¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"acquired platelet function defect"¿¡ ´ëÇÑ ´ëÇÑÀÇÇù ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
liver function test
°£±â´É°Ë»ç
loss-of-function mutation
±â´É¼Ò½Çµ¹¿¬º¯ÀÌ
municipal health function
½ÃÀÚÄ¡º¸°Ç±â´É
phonatory function
¹ß¼º±â´É
pulmonary function test
Æó±â´É°Ë»ç
reflex function
¹Ý»ç±â´É
renal function test
ÄáÆÏ±â´É°Ë»ç, ½ÅÀå±â´É°Ë»ç
somatosensory function
¸ö°¨°¢±â´É, ü¼º°¨°¢±â´É
survival function
»ýÁ¸ÇÔ¼ö
vegetative function
ÀÚÀ²±â´É
vestibular function test
¾È¶ã±â´É°Ë»ç, ÀüÁ¤±â´É°Ë»ç
visuoperceptual function assessment
½Ã°¢Áö°¢±â´ÉÆò°¡
vital function
»ý¸í±â´É
associated defect
¿¬°üÀå¾Ö
atrial septal defect
½É¹æ»çÀ̸·°á¼Õ, ½É¹æÁ߰ݰá¼Õ
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
feeling function
°¨Á¤±â´É
holding function
ÁöÁö±â´É
homeostatic function
Ç׻󼺱â´É
intuition function
Á÷°ü±â´É
isomeric function
À̼ºÁúü±â´É
municipal health function
µµ½Ãº¸°Ç±â´É
phonatory function
¹ß¼º±â´É
reflex function
¹Ý»ç±â´É
somatosensory function
¸ö°¨°¢±â´É
survival function
»ýÁ¸ÇÔ¼ö
vegetative function
Áõ½Ä´É
vital function
»ý¸í±â´É
liver function test
°£±â´É°Ë»ç
pulmonary function test
Æó±â´É°Ë»ç
renal function test
ÄáÆÏ±â´É°Ë»ç, ½ÅÀå±â´É°Ë»ç
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
acquired immunodeficiency syndrome(AIDS)
ÈÄõ¼º ¸é¿ª°áÇÌ ÁõÈıº
acquired perforating dermatosis
ÈÄõ¼º õ°ø¼º ÇǺκ´
acquired porphyria cutanea tarda
ÈÄõ¼º Áö¿¬¼º ÇǺΠÆ÷¸£ÇǸ°Áõ(~ñø)
acquired progressive lymphangioma
ÈÄõ¼º ÁøÇ༺ ¸²ÇÁ°üÁ¾
acquired reactive perforating dermatosis
ÈÄõ¼º ¹ÝÀÀ¼º õ°ø¼º ÇǺκ´
acquired resistence
ȹµæÀúÇ×¼º(¡î½ù÷àõ).
acquired tolerance
ÈÄõ(¼º) ³»¼º(¡Ò±àõ), ȹµæ°ü¿ë.
acquired tolerance
ȹµæ°ü¿ë, ÈÄõ¼º°ü¿ë
aids=£¾acquired immune deficiency syndrome
ÈÄõ¼º¸é¿ª°áÇÌÁõÈıº(ýô¸àõØóæ¹ÌÀù¹ñøý¦ÏØ)
hospital acquired (nosocomial) infection
¿ø³»°¨¿°(êÂÒ®Êïæø), º´¿ø°¨¿°.
hospital acquired infection
¿ø³»°¨¿°, º´¿ø³»°¨¿°
ichthyoacanthotoxin, acquired
ÈÄõ¼º ¾î¸°±Ø¼¼Æ÷µ¶¼Ò.
immunodeficiency syndrome, acquired
ÈÄõ¼º ¸é¿ª°áÇÌ ÁõÈıº
primary acquired cholesteatoma
ÀÏÂ÷(¼º) ÈÄõ(¼º) ÁøÁÖÁ¾
ECD=£¾endocardial cushion defect
½É³»¸·»ó°á¼Õ(Áõ).
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
hellp(hemolysis, elevated liver enzymes, low platelet),heliminths
À±Ãæ(ëÌõù)
human platelet antigens=HPA
ÀÎÇ÷¼ÒÆÇÇ׿ø
mean platelet volume
Æò±ÕÇ÷¼ÒÆÇ¿ëÀû
mean platelet volume=MPV
Æò±ÕÇ÷¼ÒÆÇ¿ëÀû
paf(platelet activating factor)
Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ(úìá³÷ù üÀàõì×í)
platelet
Ç÷¼ÒÆÇ
platelet
Ç÷¼ÒÆÇ(úìá³÷ù).
platelet
Ç÷¼ÒÆÇ(úìá³÷ù)
platelet activating factor
Ç÷¼ÒÆÇ Ȱ¼º ÀÎÀÚ
platelet adhesion
Ç÷¼ÒÆÇºÎÂø
platelet agglutination
Ç÷¼ÒÆÇÀÀÁý
platelet aggregation
Ç÷¼ÒÆÇÀÀÁý
platelet agitator
Ç÷¼ÒÆÇÈ¥ÇÕ±â
platelet antibody
Ç÷¼ÒÆÇÇ×ü(¡ù÷ô÷).
platelet concentrate
Ç÷¼ÒÆÇ³óÃà¾× (¡ÒØõêäû).
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½